ARBs with Longest Half-Life for Once-Daily Dosing
Telmisartan has the longest elimination half-life among ARBs at approximately 24 hours, followed by irbesartan with a half-life of 11-15 hours, making both excellent choices for reliable once-daily dosing. 1
Pharmacokinetic Comparison of ARBs
The elimination half-life directly impacts the duration of receptor blockade and blood pressure control throughout the 24-hour dosing interval:
Longest-Acting ARBs
- Telmisartan: Terminal elimination half-life of ~24 hours, providing the most sustained duration of action in the class 1
- Irbesartan: Half-life of 11-15 hours, second longest among ARBs with 60-80% oral bioavailability (highest in class) 2, 3
- Candesartan: Half-life of 9-15 hours with complete prodrug conversion during absorption 2, 4
Shorter-Acting ARBs
- Losartan: Shorter half-life, though partially compensated by active metabolite EXP3174 1, 2
- Valsartan: Classified as shorter-acting with elimination half-life <11 hours 2, 4
- Eprosartan: Also classified as shorter-acting 2, 4
- Olmesartan: Half-life of 10-15 hours 5
Clinical Implications for Blood Pressure Control
The longer half-life of telmisartan and irbesartan translates to more sustained AT1 receptor blockade at trough (end of dosing interval), which is clinically significant for 24-hour blood pressure control. 1, 4
Key Pharmacodynamic Differences
- Both candesartan and irbesartan demonstrate insurmountable (tight-binding) antagonism at the AT1 receptor, while losartan, valsartan, and eprosartan show competitive antagonism 4
- The slow dissociation kinetics from the AT1 receptor with longer-acting agents may enhance duration of blood pressure reduction 1
- Candesartan requires the lowest dosage among ARBs and demonstrates dose-dependent efficacy 4
Guideline-Recommended ARBs for Heart Failure
For patients requiring ARBs in heart failure with reduced ejection fraction (HFrEF), guidelines specify three agents with proven mortality benefit 6:
- Candesartan: 4-8 mg once daily, target 32 mg once daily 6
- Losartan: 25-50 mg once daily, target 50-150 mg once daily 6
- Valsartan: 20-40 mg once daily, target 160 mg twice daily 6
Note that valsartan requires twice-daily dosing to achieve target therapeutic effect in heart failure, despite being dosed once daily for hypertension. 6
Common Pitfalls
- Food interactions: Valsartan bioavailability decreases 40-50% with food, while irbesartan and telmisartan are unaffected 2, 3
- Prodrug considerations: Candesartan cilexetil requires complete conversion during GI absorption; losartan undergoes only partial hepatic conversion to active metabolite 2, 4
- Comparative efficacy: Initial trials suggest candesartan and irbesartan provide superior trough blood pressure reduction compared to losartan at recommended doses 4